Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Inclusion Criteria: Patients must be/have: * Histological evidence of malignancy * Advanced solid tumors that have recurred or progressed following standard therapy * Failed one prior therapy or have no standard therapy available * Ambulatory with ECOG of 0-1 and estimated life expectancy of \> 3 months * If female, negative pregnancy test * If of childbearing years, agree to use birth control * If patient with prior radiation therapy for brain metastases, on steroids, must have been stable for 1 month Exclusion Criteria: Patients will be excluded if they are or have had: * Prior radiation within 4 weeks * Active medical condition or organ disease which may compromise safety or interfere with the study * Clinically significant cardiac co-morbidities or pulmonary impairment * Concomitant therapy needs * Treated with any investigational drugs within 30 days * Tumors involve major artery or vein * Prior or concurrent central nervous system (CNS) disease * Less than 4 weeks since major surgery * Known to be positive for HIV, hepatitis B or C * Concurrent use of aspirin * Use of thrombolytic agents * Uncontrolled hypertension * Grade II-IV peripheral vascular disease * Pregnant or lactating * Prior allergic history to compounds of similar chemical composition * Inpatients * Grade II-IV peripheral neuropathy